High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 7, Pages 1988
Publisher
MDPI AG
Online
2023-03-27
DOI
10.3390/cancers15071988
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
- (2023) Razan Mohty et al. HAEMATOLOGICA
- Combining selinexor with alisertib to target the p53 pathway in neuroblastoma
- (2022) Rosa Nguyen et al. NEOPLASIA
- Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
- (2022) J. J. W. M. Janssen et al. LEUKEMIA
- Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy
- (2021) Ruijuan Du et al. Molecular Cancer
- Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
- (2021) Andoni Garitano-Trojaola et al. Communications Biology
- Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor
- (2021) Song Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- XPO1-dependent nuclear export as a target for cancer therapy
- (2020) Nancy G. Azizian et al. Journal of Hematology & Oncology
- Selinexor for advanced hematologic malignancies
- (2020) Janek S. Walker et al. LEUKEMIA & LYMPHOMA
- Altered nuclear export signal recognition as a driver of oncogenesis
- (2019) Justin Taylor et al. Cancer Discovery
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
- (2019) Kendra Sweet et al. CLINICAL CANCER RESEARCH
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
- (2018) Jianfang Liu et al. CELL
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- The bone-marrow niche in MDS and MGUS: implications for AML and MM
- (2018) Irene M. Ghobrial et al. Nature Reviews Clinical Oncology
- A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche
- (2018) Jlenia Guarnerio et al. Nature Communications
- CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity
- (2018) David M. Saulino et al. Oncotarget
- Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
- (2018) Weiguo Zhang et al. HAEMATOLOGICA
- CANCERTOOL: a visualization and representation interface to exploit cancer datasets
- (2018) Ana R Cortazar et al. CANCER RESEARCH
- A Seven-Gene Signature Aggregates a Subgroup of Stage II Colon Cancers with Stage III
- (2018) Sophy Laibe et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
- (2018) Vinod Vijay Subhash et al. Scientific Reports
- Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma
- (2018) Joshua Felgenhauer et al. NEOPLASIA
- AURKA contributes to the progression of oral squamous cell carcinoma (OSCC) through modulating epithelial-to-mesenchymal transition (EMT) and apoptosis via the regulation of ROS
- (2018) Hou Dawei et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
- (2018) Rossella Fioravanti et al. CHEMICAL RECORD
- Functional genomic landscape of acute myeloid leukaemia
- (2018) Jeffrey W. Tyner et al. NATURE
- Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis
- (2018) Tianci Cheng et al. MEDICAL SCIENCE MONITOR
- Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer
- (2017) Arjun Gupta et al. Journal of Thoracic Oncology
- Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner
- (2017) Konstantinos Dimopoulos et al. Molecular Oncology
- EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas
- (2017) Faizaan Mohammad et al. NATURE MEDICINE
- Aurora A Kinase Is a Priority Pharmaceutical Target for the Treatment of Cancers
- (2017) Arun Prasath Damodaran et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
- (2016) M. R. Luskin et al. BLOOD
- Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
- (2016) Ying Chen et al. CLINICAL CANCER RESEARCH
- XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II to the Nucleus
- (2016) P. Ranganathan et al. CLINICAL CANCER RESEARCH
- Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial
- (2016) Steven G. DuBois et al. JOURNAL OF CLINICAL ONCOLOGY
- Microenvironment-dependent growth of preneoplastic and malignant plasma cells in humanized mice
- (2016) Rituparna Das et al. NATURE MEDICINE
- Hematopoietic stem cell transplantation for patients with AML in first complete remission
- (2015) J. J. Cornelissen et al. BLOOD
- An update of current treatments for adult acute myeloid leukemia
- (2015) H. Dombret et al. BLOOD
- KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
- (2015) Giovanni Luca Gravina et al. BMC CANCER
- Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities
- (2015) Koen Schepers et al. Cell Stem Cell
- Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
- (2015) N. Boissel et al. HAEMATOLOGICA
- Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial
- (2015) N. Boissel et al. HAEMATOLOGICA
- Prognostic impact and targeting of CRM1 in acute myeloid leukemia
- (2013) K. Kojima et al. BLOOD
- Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
- (2013) Paul Roepman et al. INTERNATIONAL JOURNAL OF CANCER
- Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
- (2013) Ellen Weisberg et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells
- (2012) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
- (2012) Mikkel Krogh-Madsen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
- (2012) Swarnali Acharyya et al. CELL
- Mutations in the Ras-Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer
- (2012) K. Kemper et al. CLINICAL CANCER RESEARCH
- NESdb: a database of NES-containing CRM1 cargoes
- (2012) Darui Xu et al. MOLECULAR BIOLOGY OF THE CELL
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
- (2012) Matthew D. Wilkerson et al. PLoS One
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Differential niche and Wnt requirements during acute myeloid leukemia progression
- (2011) S. W. Lane et al. BLOOD
- Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia
- (2010) Alex Bogason et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
- (2010) Douglas W McMillin et al. NATURE MEDICINE
- The leukemic stem cell niche: current concepts and therapeutic opportunities
- (2009) S. W. Lane et al. BLOOD
- Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer
- (2009) R. N. Jorissen et al. CLINICAL CANCER RESEARCH
- EXPRESSION OF CRM1 IN HUMAN GLIOMAS AND ITS SIGNIFICANCE IN P27 EXPRESSION AND CLINICAL PROGNOSIS
- (2009) Aiguo Shen et al. NEUROSURGERY
- An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors
- (2009) D Chitale et al. ONCOGENE
- Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
- (2008) Kerby Shedden et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More